Dawnrays Pharmaceutical (Holdings) Ltd. (Stock Code: 2348) founded on 8^th December 1995, its subsidiaries include Suzhou Dawnrays Pharmaceutical Co., Ltd., Suzhou Dawnrays Pharmaceutical Science and Technology Co., Ltd., Dawnrays (Nantong) Pharmaceutical Science and Technology Co., Ltd., Dawnrays Pharma (Hong Kong) Ltd. and Guangdong Dawnrays Pharmaceutical Co., Ltd. The Group was listed on the Main Board of the Stock Exchange of Hong Kong on 11^th July 2003.

One of the core subsidiaries of the Group — Suzhou Dawnrays Pharmaceutical Co., Ltd. is among one of the earliest pharmaceutical companies in China granted the GMP certification; in 2001, it was recognized as the “Backbone Enterprise of Pharmaceutical Industrial Base in Wuzhong District of the National Torch Program” by the Ministry of Science and Technology of the P.R. China; in 2002, it was awarded the titles of the “New and High-tech Enterprise of Jiangsu Province” and the “Double Intensive Foreign-invested Enterprise of Jiangsu Province (in terms of technology- and knowledge-intensive)”; in 2003, it was recognized as the “Key New and High-tech Enterprise of the National Torch Program” by the Ministry of Science and Technology of the P.R. China and has been the top 100 enterprises in China’s pharmaceutical industry.

Dawnrays Pharma is principally engaged in the development, manufacturing and sales of cephalosporin antibiotics and various system specific medicines. The product range for cephalosporin antibiotics covers intermediates, bulk medicines and powder for injections; its system specific medicines cover therapeutic areas for anti-allergic, cardiovascular system, digestive system, urinary system and endocrine system and its dosage forms include tablets, capsules and granules.

The production of cephalosporin antibiotics adopts a distinctive comprehensive vertically integrated process from pharmaceutical intermediates to bulk medicines and pharmaceutical preparations. Dawnrays Pharma is equipped with advanced technology platform, in particular in the area of chemical synthesis for the 3^rd generation cephalosporins. The quality of products has reached the world-class standard, which has established an extensive product portfolio and integrated with a complete set of supplementary features and industrial chains with potentially high production capacity. Our product, Cefoperazone Sodium bulk medicine and its powder for injection by solvent crystallization was categorized as a project under the national Torch Program and was awarded the title of “New and High-tech Products of Jiangsu Province”, and it has been dominating a big market share in China.

Our core system specific medicines in the areas such as cardiovascular and endocrine systems, etc., are gradually building up the brand equity of Dawnrays Pharma. Amlodipine Besylate Tablets (brand name: “An Nei Zhen^®”) and Cetirizine Hydrochloride Tablets (brand name: “Xi Ke Wei^®”) both were the first batch of products in China received approval for launching into the market and have been the dominant market players. Amlodipine Besylate Tablets (brand name: “An Nei Zhen^®”) were awarded the title of “New and High-tech Products of Jiangsu Province” and categorized as a project under the national Torch Program; Cetirizine Hydrochloride Tablets (brand name: “Xi Ke Wei^®”) were recognized as “National Key New Products” and awarded the title of “New and High-tech Products of Jiangsu Province”, as well as being categorized as a project under the provincial Torch Program by the Department of Science and Technology of Jiangsu Province.

Dawnrays Pharma has been devoting itself to the healthcare of human beings. With the high sense of social responsibility, visionary perception, and the ever-improving and innovative technologies, the Group is committed to offer safe and effective drugs with supreme quality and become a leading player in China's pharmaceutical industry.